Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7

Vera Therapeutics, Inc.

2026-Q1 EPS reported -$1.69

Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.
Cash, equivalents and marketable securities at $596.8M; expects to fund operations beyond expected launch.
FDA accepted atacicept BLA for priority review with PDUFA date of July 7, 2026 for IgAN.
Matt Skelton promoted to CCO; Jane Wright-Mitchell appointed Chief Legal Officer; Christopher Hite added to board.
Initial Phase 2 PIONEER basket trial results expected Q2 2026; pivotal eGFR data from ORIGIN 3 expected Q1 2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vera Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income a net loss of $121.0 million, EPS a net loss per diluted share of $1.69.

Period: first quarter ended March 31, 2026
Net income: a net loss of $121.0 million
EPS: a net loss per diluted share of $1.69
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2026, Vera Therapeutics reported a net loss of $121.0 million, or a net loss per diluted share of $1.69

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210351

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.